ID   MP2K4_HUMAN             Reviewed;         399 AA.
AC   P45985; B2R7N7; B3KYB2; D3DTS5; Q5U0B8; Q6FHX4; Q6P9H2; Q6PIE6;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   10-MAY-2017, entry version 176.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 4;
DE            Short=MAP kinase kinase 4;
DE            Short=MAPKK 4;
DE            EC=2.7.12.2;
DE   AltName: Full=JNK-activating kinase 1;
DE   AltName: Full=MAPK/ERK kinase 4;
DE            Short=MEK 4;
DE   AltName: Full=SAPK/ERK kinase 1;
DE            Short=SEK1;
DE   AltName: Full=Stress-activated protein kinase kinase 1;
DE            Short=SAPK kinase 1;
DE            Short=SAPKK-1;
DE            Short=SAPKK1;
DE   AltName: Full=c-Jun N-terminal kinase kinase 1;
DE            Short=JNKK;
GN   Name=MAP2K4; Synonyms=JNKK1, MEK4, MKK4, PRKMK4, SEK1, SERK1, SKK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7839144; DOI=10.1126/science.7839144;
RA   Derijard B., Raingeaud J., Barrett T., Wu I.-H., Han J.,
RA   Ulevitch R.J., Davis R.J.;
RT   "Independent human MAP-kinase signal transduction pathways defined by
RT   MEK and MKK isoforms.";
RL   Science 267:682-685(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=7716521; DOI=10.1126/science.7716521;
RA   Lin A., Minden A., Martinetto H., Claret F.-X., Lange-Carter C.,
RA   Mercurio F., Johnson G.L., Karin M.;
RT   "Identification of a dual specificity kinase that activates the Jun
RT   kinases and p38-Mpk2.";
RL   Science 268:286-290(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9622070;
RA   Su G.H., Hilgers W., Shekher M.C., Tang D.J., Yeo C.J., Hruban R.H.,
RA   Kern S.E.;
RT   "Alterations in pancreatic, biliary, and breast carcinomas support
RT   MKK4 as a genetically targeted tumor suppressor gene.";
RL   Cancer Res. 58:2339-2342(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   ARG-16.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   PHOSPHORYLATION AT THR-261, ENZYME REGULATION, AND INTERACTION WITH
RP   MAP3K11/MLK3.
RX   PubMed=9003778;
RA   Tibbles L.A., Ing Y.L., Kiefer F., Chan J., Iscove N., Woodgett J.R.,
RA   Lassam N.J.;
RT   "MLK-3 activates the SAPK/JNK and p38/RK pathways via SEK1 and
RT   MKK3/6.";
RL   EMBO J. 15:7026-7035(1996).
RN   [12]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   PubMed=11104681; DOI=10.1042/bj3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [13]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11090355; DOI=10.1126/science.290.5496.1574;
RA   McDonald P.H., Chow C.W., Miller W.E., Laporte S.A., Field M.E.,
RA   Lin F.-T., Davis R.J., Lefkowitz R.J.;
RT   "Beta-arrestin 2: a receptor-regulated MAPK scaffold for the
RT   activation of JNK3.";
RL   Science 290:1574-1577(2000).
RN   [14]
RP   INTERACTION WITH MAPK8IP3/JIP3.
RX   PubMed=12189133; DOI=10.1074/jbc.M202004200;
RA   Matsuura H., Nishitoh H., Takeda K., Matsuzawa A., Amagasa T., Ito M.,
RA   Yoshioka K., Ichijo H.;
RT   "Phosphorylation-dependent scaffolding role of JSAP1/JIP3 in the ASK1-
RT   JNK signaling pathway. A new mode of regulation of the MAP kinase
RT   cascade.";
RL   J. Biol. Chem. 277:40703-40709(2002).
RN   [15]
RP   DOMAIN, AND INTERACTION WITH MAPK8/JNK1; MAPK9/JNK2; MAPK10/JNK3;
RP   MAPK11 AND MAPK14.
RX   PubMed=12788955; DOI=10.1074/jbc.M304229200;
RA   Ho D.T., Bardwell A.J., Abdollahi M., Bardwell L.;
RT   "A docking site in MKK4 mediates high affinity binding to JNK MAPKs
RT   and competes with similar docking sites in JNK substrates.";
RL   J. Biol. Chem. 278:32662-32672(2003).
RN   [16]
RP   DOMAIN.
RX   PubMed=15866172; DOI=10.1016/j.molcel.2005.04.001;
RA   Takekawa M., Tatebayashi K., Saito H.;
RT   "Conserved docking site is essential for activation of mammalian MAP
RT   kinase kinases by specific MAP kinase kinase kinases.";
RL   Mol. Cell 18:295-306(2005).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-90, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [19]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=19782076; DOI=10.1016/j.febslet.2009.09.035;
RA   Li X., MacLeod R., Dunlop A.J., Edwards H.V., Advant N., Gibson L.C.,
RA   Devine N.M., Brown K.M., Adams D.R., Houslay M.D., Baillie G.S.;
RT   "A scanning peptide array approach uncovers association sites within
RT   the JNK/beta arrestin signalling complex.";
RL   FEBS Lett. 583:3310-3316(2009).
RN   [20]
RP   REVIEW ON ENZYME REGULATION.
RX   PubMed=17496909; DOI=10.1038/sj.onc.1210392;
RA   Raman M., Chen W., Cobb M.H.;
RT   "Differential regulation and properties of MAPKs.";
RL   Oncogene 26:3100-3112(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [22]
RP   REVIEW ON FUNCTION.
RX   PubMed=20801953; DOI=10.1093/jb/mvq098;
RA   Asaoka Y., Nishina H.;
RT   "Diverse physiological functions of MKK4 and MKK7 during early
RT   embryogenesis.";
RL   J. Biochem. 148:393-401(2010).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   REVIEW ON REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21333379; DOI=10.1016/j.ejcb.2010.11.008;
RA   Haeusgen W., Herdegen T., Waetzig V.;
RT   "The bottleneck of JNK signaling: molecular and functional
RT   characteristics of MKK4 and MKK7.";
RL   Eur. J. Cell Biol. 90:536-544(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-257, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   METHYLATION [LARGE SCALE ANALYSIS] AT ARG-58, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 80-399.
RX   PubMed=20732303; DOI=10.1016/j.bbrc.2010.08.071;
RA   Matsumoto T., Kinoshita T., Kirii Y., Yokota K., Hamada K., Tada T.;
RT   "Crystal structures of MKK4 kinase domain reveal that substrate
RT   peptide binds to an allosteric site and induces an auto-inhibition
RT   state.";
RL   Biochem. Biophys. Res. Commun. 400:369-373(2010).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-142; TRP-154; ILE-234; ASN-251 AND
RP   THR-279.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Dual specificity protein kinase which acts as an
CC       essential component of the MAP kinase signal transduction pathway.
CC       Essential component of the stress-activated protein kinase/c-Jun
CC       N-terminal kinase (SAP/JNK) signaling pathway. With MAP2K7/MKK7,
CC       is the one of the only known kinase to directly activate the
CC       stress-activated protein kinase/c-Jun N-terminal kinases
CC       MAPK8/JNK1, MAPK9/JNK2 and MAPK10/JNK3. MAP2K4/MKK4 and
CC       MAP2K7/MKK7 both activate the JNKs by phosphorylation, but they
CC       differ in their preference for the phosphorylation site in the
CC       Thr-Pro-Tyr motif. MAP2K4 shows preference for phosphorylation of
CC       the Tyr residue and MAP2K7/MKK7 for the Thr residue. The
CC       phosphorylation of the Thr residue by MAP2K7/MKK7 seems to be the
CC       prerequisite for JNK activation at least in response to
CC       proinflammatory cytokines, while other stimuli activate both
CC       MAP2K4/MKK4 and MAP2K7/MKK7 which synergistically phosphorylate
CC       JNKs. MAP2K4 is required for maintaining peripheral lymphoid
CC       homeostasis. The MKK/JNK signaling pathway is also involved in
CC       mitochondrial death signaling pathway, including the release
CC       cytochrome c, leading to apoptosis. Whereas MAP2K7/MKK7
CC       exclusively activates JNKs, MAP2K4/MKK4 additionally activates the
CC       p38 MAPKs MAPK11, MAPK12, MAPK13 and MAPK14.
CC       {ECO:0000269|PubMed:7716521}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Activated in response to a variety of cellular
CC       stresses, including UV and gamma-irradiation, heat shock,
CC       hyperosmolarity, T-cell receptor stimulation, peroxide and
CC       inflammatory cytokines. Also activated by developmental cues.
CC       MAP2K4/MKK4 is activated by the majority of MKKKs, such as
CC       MAP3K5/ASK1, MAP3K1/MEKK1, MAP3K7/TAK1, MAP3K10/MLK2,
CC       MAP3K11/MLK3, MAP3K12/DLK and MAP3K13/LZK.
CC       {ECO:0000269|PubMed:9003778}.
CC   -!- SUBUNIT: Interacts with SPAG9 (By similarity). Interacts (via its
CC       D domain) with its substrates MAPK8/JNK1, MAPK9/JNK2, MAPK10/JNK3,
CC       MAPK11 and MAPK14. Interacts (via its DVD domain) with MAP3Ks
CC       activators like MAP3K1/MEKK1 and MAP3K11/MLK3. Interacts with
CC       ARRB1, ARRB2 and MAPK8IP3/JIP3. {ECO:0000250,
CC       ECO:0000269|PubMed:11090355, ECO:0000269|PubMed:12189133,
CC       ECO:0000269|PubMed:12788955, ECO:0000269|PubMed:19782076,
CC       ECO:0000269|PubMed:9003778}.
CC   -!- INTERACTION:
CC       Q13233:MAP3K1; NbExp=3; IntAct=EBI-447868, EBI-49776;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Nucleus
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P45985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P45985-2; Sequence=VSP_038838;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Abundant expression is seen in the skeletal
CC       muscle. It is also widely expressed in other tissues.
CC   -!- DOMAIN: The DVD domain (residues 364-387) contains a conserved
CC       docking site and is found in the mammalian MAP kinase kinases
CC       (MAP2Ks). The DVD sites bind to their specific upstream MAP kinase
CC       kinase kinases (MAP3Ks) and are essential for activation.
CC   -!- DOMAIN: The D domain (residues 34-52) contains a conserved docking
CC       site and is required for the binding to MAPK substrates.
CC   -!- PTM: Activated by phosphorylation on Ser-257 and Thr-261 by MAP
CC       kinase kinase kinases (MAP3Ks). {ECO:0000269|PubMed:9003778}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/map2k4/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/MAP2K4ID244ch17p12.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L36870; AAC41719.1; -; mRNA.
DR   EMBL; U17743; AAC50127.1; -; mRNA.
DR   EMBL; AF070090; AAC24130.1; -; Genomic_DNA.
DR   EMBL; AF070080; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070081; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070082; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070083; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070084; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070085; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070086; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070087; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070088; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; AF070089; AAC24130.1; JOINED; Genomic_DNA.
DR   EMBL; CR536564; CAG38801.1; -; mRNA.
DR   EMBL; BT019676; AAV38482.1; -; mRNA.
DR   EMBL; AK131544; BAG54774.1; -; mRNA.
DR   EMBL; AK313053; BAG35884.1; -; mRNA.
DR   EMBL; DQ015703; AAY22176.1; -; Genomic_DNA.
DR   EMBL; AC005244; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005410; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471108; EAW89975.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89974.1; -; Genomic_DNA.
DR   EMBL; CH471108; EAW89976.1; -; Genomic_DNA.
DR   EMBL; BC036032; AAH36032.1; -; mRNA.
DR   EMBL; BC060764; AAH60764.1; -; mRNA.
DR   CCDS; CCDS11162.1; -. [P45985-1]
DR   CCDS; CCDS62095.1; -. [P45985-2]
DR   PIR; I38901; I38901.
DR   RefSeq; NP_001268364.1; NM_001281435.1. [P45985-2]
DR   RefSeq; NP_003001.1; NM_003010.3. [P45985-1]
DR   UniGene; Hs.514681; -.
DR   PDB; 3ALN; X-ray; 2.30 A; A/B/C=80-399.
DR   PDB; 3ALO; X-ray; 2.60 A; A=80-399.
DR   PDB; 3VUT; X-ray; 3.50 A; A/B=80-399.
DR   PDBsum; 3ALN; -.
DR   PDBsum; 3ALO; -.
DR   PDBsum; 3VUT; -.
DR   ProteinModelPortal; P45985; -.
DR   SMR; P45985; -.
DR   BioGrid; 112315; 41.
DR   IntAct; P45985; 16.
DR   MINT; MINT-151438; -.
DR   STRING; 9606.ENSP00000262445; -.
DR   BindingDB; P45985; -.
DR   ChEMBL; CHEMBL2897; -.
DR   GuidetoPHARMACOLOGY; 2065; -.
DR   iPTMnet; P45985; -.
DR   PhosphoSitePlus; P45985; -.
DR   BioMuta; MAP2K4; -.
DR   DMDM; 1170596; -.
DR   EPD; P45985; -.
DR   MaxQB; P45985; -.
DR   PaxDb; P45985; -.
DR   PeptideAtlas; P45985; -.
DR   PRIDE; P45985; -.
DR   DNASU; 6416; -.
DR   Ensembl; ENST00000353533; ENSP00000262445; ENSG00000065559. [P45985-1]
DR   Ensembl; ENST00000415385; ENSP00000410402; ENSG00000065559. [P45985-2]
DR   GeneID; 6416; -.
DR   KEGG; hsa:6416; -.
DR   UCSC; uc002gnj.5; human. [P45985-1]
DR   CTD; 6416; -.
DR   DisGeNET; 6416; -.
DR   GeneCards; MAP2K4; -.
DR   HGNC; HGNC:6844; MAP2K4.
DR   HPA; CAB007751; -.
DR   HPA; HPA060074; -.
DR   MIM; 601335; gene.
DR   neXtProt; NX_P45985; -.
DR   OpenTargets; ENSG00000065559; -.
DR   PharmGKB; PA30589; -.
DR   eggNOG; KOG0984; Eukaryota.
DR   eggNOG; ENOG410XT3F; LUCA.
DR   GeneTree; ENSGT00760000119199; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P45985; -.
DR   KO; K04430; -.
DR   OMA; KFYKFIC; -.
DR   OrthoDB; EOG091G0A9H; -.
DR   PhylomeDB; P45985; -.
DR   TreeFam; TF350701; -.
DR   BRENDA; 2.7.12.2; 2681.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-HSA-450321; JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1.
DR   Reactome; R-HSA-5210891; Uptake and function of anthrax toxins.
DR   Reactome; R-HSA-5684264; MAP3K8 (TPL2)-dependent MAPK1/3 activation.
DR   SignaLink; P45985; -.
DR   SIGNOR; P45985; -.
DR   ChiTaRS; MAP2K4; human.
DR   EvolutionaryTrace; P45985; -.
DR   GeneWiki; MAP2K4; -.
DR   GenomeRNAi; 6416; -.
DR   PMAP-CutDB; P45985; -.
DR   PRO; PR:P45985; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000065559; -.
DR   CleanEx; HS_MAP2K4; -.
DR   ExpressionAtlas; P45985; baseline and differential.
DR   Genevisible; P45985; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0032839; C:dendrite cytoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0008545; F:JUN kinase kinase activity; IEA:Ensembl.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; TAS:ProtInc.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0072709; P:cellular response to sorbitol; IEA:Ensembl.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007254; P:JNK cascade; TAS:Reactome.
DR   GO; GO:2000672; P:negative regulation of motor neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0045740; P:positive regulation of DNA replication; IEA:Ensembl.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051770; P:positive regulation of nitric-oxide synthase biosynthetic process; IEA:Ensembl.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0035897; P:proteolysis in other organism; TAS:Reactome.
DR   GO; GO:0009611; P:response to wounding; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Apoptosis;
KW   ATP-binding; Complete proteome; Cytoplasm; Kinase; Methylation;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Stress response;
KW   Transferase; Tyrosine-protein kinase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    399       Dual specificity mitogen-activated
FT                                protein kinase kinase 4.
FT                                /FTId=PRO_0000086381.
FT   DOMAIN      102    367       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     108    116       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       37     52       D domain.
FT   REGION      364    387       DVD domain.
FT   COMPBIAS      5     19       Gly/Ser-rich.
FT   ACT_SITE    229    229       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     131    131       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   SITE         45     46       Cleavage; by anthrax lethal factor.
FT   SITE         58     59       Cleavage; by anthrax lethal factor.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES      58     58       Asymmetric dimethylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      58     58       Omega-N-methylarginine; alternate.
FT                                {ECO:0000244|PubMed:24129315}.
FT   MOD_RES      90     90       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     257    257       Phosphoserine; by MAP3K.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     261    261       Phosphothreonine; by MAP3K.
FT                                {ECO:0000269|PubMed:9003778}.
FT   VAR_SEQ      39     39       G -> GFQINFCEKAQS (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038838.
FT   VARIANT      16     16       S -> R (in dbSNP:rs17855590).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_062963.
FT   VARIANT     142    142       Q -> L (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040818.
FT   VARIANT     154    154       R -> W (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040819.
FT   VARIANT     234    234       N -> I (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040820.
FT   VARIANT     251    251       S -> N (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040821.
FT   VARIANT     279    279       A -> T (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs753665559).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040822.
FT   CONFLICT    118    118       K -> R (in Ref. 4; CAG38801).
FT                                {ECO:0000305}.
FT   CONFLICT    179    179       E -> G (in Ref. 6; BAG35884).
FT                                {ECO:0000305}.
FT   CONFLICT    356    356       P -> L (in Ref. 10; AAH60764).
FT                                {ECO:0000305}.
FT   STRAND       81     83       {ECO:0000244|PDB:3VUT}.
FT   STRAND       85     88       {ECO:0000244|PDB:3ALN}.
FT   STRAND       93     95       {ECO:0000244|PDB:3ALN}.
FT   STRAND      101    103       {ECO:0000244|PDB:3ALN}.
FT   STRAND      107    110       {ECO:0000244|PDB:3ALN}.
FT   STRAND      112    121       {ECO:0000244|PDB:3ALN}.
FT   TURN        122    124       {ECO:0000244|PDB:3ALN}.
FT   STRAND      127    134       {ECO:0000244|PDB:3ALN}.
FT   HELIX       139    153       {ECO:0000244|PDB:3ALN}.
FT   STRAND      164    169       {ECO:0000244|PDB:3ALN}.
FT   STRAND      171    178       {ECO:0000244|PDB:3ALN}.
FT   STRAND      182    184       {ECO:0000244|PDB:3ALN}.
FT   HELIX       185    194       {ECO:0000244|PDB:3ALN}.
FT   HELIX       202    223       {ECO:0000244|PDB:3ALN}.
FT   HELIX       232    234       {ECO:0000244|PDB:3ALN}.
FT   STRAND      235    237       {ECO:0000244|PDB:3ALN}.
FT   STRAND      243    245       {ECO:0000244|PDB:3ALN}.
FT   STRAND      249    251       {ECO:0000244|PDB:3ALN}.
FT   STRAND      255    259       {ECO:0000244|PDB:3VUT}.
FT   STRAND      267    270       {ECO:0000244|PDB:3ALO}.
FT   HELIX       272    274       {ECO:0000244|PDB:3ALO}.
FT   HELIX       287    302       {ECO:0000244|PDB:3ALN}.
FT   STRAND      312    314       {ECO:0000244|PDB:3ALO}.
FT   STRAND      316    321       {ECO:0000244|PDB:3ALO}.
FT   HELIX       338    347       {ECO:0000244|PDB:3ALN}.
FT   HELIX       352    354       {ECO:0000244|PDB:3ALN}.
FT   HELIX       358    361       {ECO:0000244|PDB:3ALN}.
FT   HELIX       365    372       {ECO:0000244|PDB:3ALN}.
FT   HELIX       377    387       {ECO:0000244|PDB:3ALN}.
SQ   SEQUENCE   399 AA;  44288 MW;  A472537F2F26770B CRC64;
     MAAPSPSGGG GSGGGSGSGT PGPVGSPAPG HPAVSSMQGK RKALKLNFAN PPFKSTARFT
     LNPNPTGVQN PHIERLRTHS IESSGKLKIS PEQHWDFTAE DLKDLGEIGR GAYGSVNKMV
     HKPSGQIMAV KRIRSTVDEK EQKQLLMDLD VVMRSSDCPY IVQFYGALFR EGDCWICMEL
     MSTSFDKFYK YVYSVLDDVI PEEILGKITL ATVKALNHLK ENLKIIHRDI KPSNILLDRS
     GNIKLCDFGI SGQLVDSIAK TRDAGCRPYM APERIDPSAS RQGYDVRSDV WSLGITLYEL
     ATGRFPYPKW NSVFDQLTQV VKGDPPQLSN SEEREFSPSF INFVNLCLTK DESKRPKYKE
     LLKHPFILMY EERAVEVACY VCKILDQMPA TPSSPMYVD
//
